Фармакотерапия хронических заболеваний вен: возможности сулодексида
Аннотация
Хронические заболевания вен (ХЗВ) относятся к наиболее распространенным патологиям периферических сосудов. Этими заболеваниями страдают более половины населения мира. ХЗВ имеют не только большое медицинское значение, но также оказывают значительный социально-экономический эффект, который только усиливается омоложением этого заболевания в последние годы. Одним из компонентов комплексной терапии ХЗВ являются антикоагулянты прямого действия, в частности сулодексид (Вессел Дуэ Ф, «Альфа Вассерманн»). При лечении ХЗВ, сопровождающихся отеками и трофическими нарушениями, сулодексид может способствовать замедлению прогрессирования признаков и симптомов заболевания у пациентов со всеми клиническими классами тяжести ХЗВ (от С1 до С6).
Список литературы
1. Коваленко В., Калитко И., Темрезов М., Чемурзиев Р., Петров А. Возможности лечения больных с атеротромботичес-ким поражением артерий нижних конечностей. Врач, 2010, 3: 1-3.
2. Российские клинические рекомендации по диагностике и лечению хронических заболеваний вен. Флебология, 2013, 2: 47.
3. Токмакова А.Ю., Анциферов М.Б., Дедов И.И. Медикаментозная терапия ишемии нижних конечностей у больных сахарным диабетом 2-го типа. Сахарный диабет, 1999, 16: 39-42.
4. Аndreozzi GM, Cordova RM, Scomparin A et ai. Quality of life in chronic venous insufficiency. An Italian pilot study of the Triveneto Region. Int Angiol., 2005, 24(3): 272-7.
5. Andreozzi G.M., Paiareti G. Rationale and study design of the SURVET trial (Suiodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis).Pathophysioiogy of hemostasis and thrombosis. Proceedings for the 21st International Congress on Thrombosis, Milan, July 5-9, 2010; 37:9-10, p.302.
6. Andreozzi GM. Suiodexide in the treatment of chronic venous disease. Am J Cardiovasc Drugs, 2012; doi 10.2165.
7. Bergan JJ, Schmid-Schonbein GW, Smith PD, et ai. Chronic venous disease. N Engl J Med, 2006, 3; 355(5):488-98.
8. Capone-Braga M, Teiiini L, Boncompagni L, et ai. Suiodexide treatment approach in patients with atheroscierotic vascuiar disease with various iocaiizations. Clin Ter, 1987, 15; 120 (1):25-31.
9. Carpentier PH, Maricq HR, Biro C, et ai. Prevaience, risk factors and ciinicai patterns of chronic venous disorders of iower iimbs. A popuiation-based study in France. J VascSurg, 2004, 40: 650-659.
10. Cirujeda LJ, Granado CP. A study on the safety, efficacy, and efficiency of suiodexide compared with acenocumaroi in secondary prophyiaxis in patients with deep venous thrombosis. Angiology, 2-6, 57(1): 53-64.
11. Ciszewicz M, Poiubinska A, Antoniewicz AA et ai. Suiodexide suppresses infiammation in human endotheiiai ceiis and prevents giucose cytotoxicity. Transl Res, 2009, 153(3): 118-23.
12. Coccheri S, Scondotto G, Agneiii G, Aioisi D et ai. Randomised, doubie-biind, muiticentre, piacebo controiied study of suiodexide in the treatment of venous ieg uicers. Thromb Haemost, 2002, 87:947-52.
13. Coccheri S, Scondotto G, Agneiii G, Paiazzini E et ai. Suiodexide in the treatment of intermittent ciaudication. Resuits of a randomised, doubie-biind, muiticentre, piacebo-controiied study. European Heart Journal, 2002, 23:1057-1065.
14. Cosmi B, Cini M, Legnani C, et ai. Additive thrombin inhibition by fast moving heparin and dermatan suifate expiains the anti-coaguiant effect of suiodexide? A naturai mixture of giy-cosaminogiicans. Thromb Res, 2003, 15, 109 (5-6):333-9.
15. Cospite M, Ferrara F, Cospite V, Paiazzini E. Suiodexide and the microcircuiatory component in microphiebopathies. Current Medical Research and Opinion, 1992, 13(1): 56-60.
16. Current aspects in chronic venous disease: focus on suiodex-ide. International Angiology, 2014, 33(3): 209-274.
17. Errichi BM, Cesarone MR, Beicaro G, Marinucci R et ai. Prevention of recurrent deep venous thrombosis with suiodexide: The SanVai Registry. Angiology, 2004, 55(3): 243-249.
18. Gaddi A, Gaietti C, Iiiuminati B, Nascetti S. Meta-anaiysis of some resuits of ciinicai triais on suiodexide therapy in periph-erai occiusive arteriai disease. The Journal of International Medical Research, 1996, 24: 389-406.
19. Gioviczki P, Comerota AJ, Daising MC et ai. The care of patients with varicose veins and associated chronic venous diseases: ciinicai practice guideiines of the Society for Vascuiar Surgery and the American Venous Forum. J Vasc Surg, 2011, 53(5): 2S-48S.
20. Guideiines Itaiian Coiiege of Phieboiogy Revision 2013. International Angiology, 2013, 32, Suppi.1 to issue No 4, 140p.
21. Jawien A, Grzeia T, Ochwat A. Prevaience of chronic venous insufficiency in men and women in Poiand: muiticenter cross-sectionai study in 40 095 patients. Phlebology, 2003, 18: 110-121.
22. Kearon C, Kahn SR, Agneiii G, et ai. Antothrombotic therapy for venous thromboemboiic disease: American Coiiege of Chest Physicians evidence-based ciinicai practice guideiines (8th ed.). Chest, 2008, 133(6): 454S-545S.
23. Kistner RL, Ekiof B, Masuda EM. Diagnosis of chronic venous disease of the iower extremities: the «CEAP» ciassification. Mayo Ciin Proc, 1996; 71: 338-345.
24. Kucharzewski M, Franek A, Kozioiek H. Treatment of venous ieg uicers with suiodexide. Phlebologie, 2003, 32: 115-20.
25. Lauver DA, Booth EA, White AJ et ai. Suiodexide attenuates myocardiai ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. J Pharmacol Exp Ther, 2005, 312(2): 794-800.
26. Maneiio F, Raffetto JD. Matrix metaiioproteinase activity and giycosaminogiycans in chronic venous disease: the iinkage among ceii bioiogy, pathoiogy and transiationai research. Am J Transl Res, 2011, 3(2): 149-58.
27. Mauro M, Paimieri GC, Paiazzini E, et ai. Pharmacodynamic effects of singie and repeated doses of orai suiodexide in heaithy voiunteers: a piacebo-controiied study with an enteric-coated formuiation. Curr Med Res Opin, 1993, 13(2): 96-108.
28. Messa GL, La Piaca G, Puccetti L, et ai. Pharmacodynamic effects of suiodexide on profibrinoiytic and haemorrheoiogicai patterns. Clin DrugInvestig, 1995, 10(3): 165-71.
29. Neison EA, Cuiium N, Jones J. Venous ieg uicers. Clin Evid, 2006, 15: 2607-26.
30. Neison EA, Jones J. Venous ieg uicers. Clin Evid (online), 2008.
31. Nicoiaides AN. Chronic venous disease and the ieukocyte-endotheiium interaction: from symptoms to uiceration. Angiology, 2005 Sep-Oct; 56 Suppi.1 S11-9.
32. Ofosu FA. Pharmacoiogicai actions of suiodexide. Seminars on thrombosis and hemostasis. 1998, 24(2): 127-138
33. Pannier F, Rabe E. Progression of Chronic Venous Disorders: Resuits from the Bonn Vein Study. Journal of Vasc Surg, 2001, 53(1): 254-255.
34. Pinto A, Corrao S, Gaiati D, Arnone S et ai. Suiodexide versus caicium heparin in the medium-term treatment of deep vein thrombosis of the iower iimbs. Angiology. The Journal of Vascular Diseases, 1997, 48(9): 805-811.
35. Rabe E, Pannier F. What have we iearned from the Bonn study. Phlebolymphology, 2006, 13(4): 188-193.
36. Saviano M, Maieti 0, Liguori L. Doubie-biind,doubie-dummy, randomized,muiticentre ciinicai assessment of the efficacy, toierabiiity, and dose-effect reiationship of suiodexide in chronic venous insufficiency. ^rr Med Res Opin, 1993, 13(2): 96-108.
37. Scondotto G, Aioisi D, Ferrari P, et ai. Treatment of venous ieg uicers with suiodexide. Angiology, 1999, 50(11): 883-9.
38. Takase S, Bergan JJ, Schmid-Schonbein G. Expression of adhesion moiecuies and cytokines on saphenous veins in chronic venous insufficiency. Ann Vasc Surg, 2000, 14(5): 427-35.
Рецензия
Для цитирования:
Ширинбек О... Фармакотерапия хронических заболеваний вен: возможности сулодексида. Амбулаторная хирургия. 2015;(1-2):26-30.
Просмотров: 650
Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International.
Послать статью по эл. почте 